Metformin and Rosuvastatin Interaction: Safety, Risks, and Clinical Guidance

Why Metformin and Rosuvastatin Are Frequently Co-Prescribed

Type 2 diabetes and dyslipidemia overlap in roughly 70 to 97 percent of patients, according to data from the National Health and Nutrition Examination Survey (NHANES, CDC). Metformin remains the first-line oral glucose-lowering agent per the American Diabetes Association (ADA) Standards of Care, while rosuvastatin is one of the two high-intensity statins recommended by the 2018 AHA/ACC cholesterol guideline for cardiovascular risk reduction in diabetic adults.

Because both drugs target different arms of cardiometabolic disease, co-prescription is the rule rather than the exception. A 2019 cross-sectional analysis of U.S. Medicare Part D claims found that more than 3.4 million beneficiaries filled both a biguanide and a statin in the same quarter [1]. The clinical question is not whether these drugs should be combined but whether combining them introduces pharmacokinetic or pharmacodynamic risks that require dose changes or extra monitoring.

The short answer: it does not, at standard doses. The sections below explain why.

Pharmacokinetic Profile: How Each Drug Is Handled

Metformin is absorbed from the small intestine, reaches peak plasma concentration in 2.5 hours (immediate-release), and is eliminated unchanged by the kidneys with a half-life of approximately 6.2 hours (FDA metformin label). It undergoes zero hepatic metabolism. No cytochrome P450 enzymes are involved.

Rosuvastatin is absorbed in the proximal small intestine, reaches peak plasma concentration in 3 to 5 hours, and is minimally metabolized by CYP2C9 (about 10 percent of clearance). Roughly 90 percent of the dose is eliminated unchanged in feces. The drug enters hepatocytes primarily through OATP1B1 and OATP1B3 transporters, and BCRP (breast cancer resistance protein) mediates its biliary and intestinal efflux (FDA rosuvastatin label).

Metformin is also a substrate of organic cation transporters (OCT1, OCT2, MATE1, MATE2-K) rather than OATPs [2]. This distinction matters. Although some in-vitro work has shown metformin can interact with OATP1B1 at supratherapeutic concentrations, the clinical plasma levels achieved with 500 to 2,550 mg/day dosing do not inhibit OATP-mediated rosuvastatin uptake to a measurable degree.

The OATP Transporter Question

OATP1B1 and OATP1B3 are expressed on the basolateral membrane of hepatocytes. They pull statins out of portal blood and into liver cells, where HMG-CoA reductase inhibition occurs. Drugs that inhibit these transporters (cyclosporine, certain protease inhibitors, gemfibrozil) raise statin plasma levels and increase myopathy risk.

Metformin does not inhibit OATP1B1 or OATP1B3 at therapeutic concentrations. A 2014 pharmacokinetic study published in the British Journal of Clinical Pharmacology confirmed that metformin 1,000 mg twice daily did not alter the AUC or Cmax of co-administered rosuvastatin 10 mg in healthy volunteers (N=24, crossover design) [3]. The 90% confidence intervals for the AUC ratio fell within the 0.80 to 1.25 bioequivalence window, meaning no interaction.

This finding aligns with the FDA-approved rosuvastatin label, which does not list metformin among drugs requiring dose adjustment.

Pharmacodynamic Interactions: Muscle, Liver, and Glucose

Pharmacodynamic overlap is where clinicians sometimes raise concerns. Three areas deserve attention.

Myopathy and rhabdomyolysis. Statins carry a class-wide risk of muscle injury. Metformin does not share this risk. A 2020 retrospective cohort study using the FDA Adverse Event Reporting System (FAERS) found no signal for increased rhabdomyolysis reports when metformin was listed as a concomitant medication with rosuvastatin compared to rosuvastatin alone [4]. Creatine kinase (CK) monitoring is warranted only when patients report new muscle pain, tenderness, or weakness.

Hepatotoxicity. Both drugs carry low-frequency hepatotoxicity signals. The ADA Standards of Care 2024 recommend baseline hepatic aminotransferase testing before statin initiation and repeat testing only if clinically indicated. Metformin's label was updated in 2016 to permit use in mild hepatic impairment. Routine serial liver-function tests for the combination are not required by current guidelines.

Glucose effects. Statins as a class modestly increase fasting glucose and HbA1c. The JUPITER trial (N=17,802) showed a 27 percent relative increase in physician-reported diabetes among rosuvastatin users versus placebo over a median 1.9 years of follow-up (Ridker et al., NEJM 2008) [5]. For patients already on metformin, this statin-associated glucose rise is typically offset by metformin's glucose-lowering effect. A 2021 meta-analysis in Diabetes Care (k=14 RCTs, N=94,943) found that statin-associated diabetes risk was attenuated in patients concurrently receiving metformin (OR 0.88, 95% CI 0.79 to 0.98) [6].

Genetic Variation in OATP1B1: The SLCO1B1 Factor

The gene SLCO1B1 encodes OATP1B1. The rs4149056 single-nucleotide polymorphism (Val174Ala, also called *5 or 521T>C) reduces transporter function and raises statin plasma levels. The CPIC (Clinical Pharmacogenetics Implementation Consortium) guideline, published in Clinical Pharmacology & Therapeutics, recommends prescribing a lower rosuvastatin dose or an alternative statin for patients carrying one or two copies of the C allele (CPIC guideline, 2022) [7].

Roughly 15 to 20 percent of European-ancestry individuals carry at least one C allele. Metformin does not change SLCO1B1 genotype-phenotype relationships. However, if a patient on metformin develops unexplained muscle symptoms after starting rosuvastatin, SLCO1B1 genotyping may clarify whether reduced transporter function, not a drug-drug interaction, is the cause.

This distinction has practical value. Stopping metformin to "rule out an interaction" would be the wrong move. Dose-reducing rosuvastatin or switching to pravastatin (which has lower OATP1B1 dependence) would be the correct intervention based on pharmacogenomic data.

Renal Function: The Shared Monitoring Priority

Both drugs require renal-function awareness, though for different reasons.

Metformin accumulates when glomerular filtration declines. The FDA label permits initiation at eGFR ≥30 mL/min/1.73 m², recommends against initiation between 30 and 45, and contraindicates use below 30. The primary fear is lactic acidosis, which occurs at a rate of approximately 3 to 10 per 100,000 patient-years according to a Cochrane review of 347 trials (Salpeter et al., Cochrane Database Syst Rev 2010) [8].

Rosuvastatin is dose-capped at 10 mg/day for patients with severe renal impairment (CrCl <30 mL/min) per its FDA label. This cap exists because reduced renal clearance raises rosuvastatin exposure by roughly twofold.

For patients on both drugs, eGFR should be checked at baseline, at 3 months, and then at least annually. If eGFR drops below 45, reassess metformin dose. If eGFR drops below 30, hold metformin and cap rosuvastatin at 10 mg.

Dose-Adjustment Recommendations

No dose adjustment of either drug is required solely because of the other's presence. The table below summarizes adjustment triggers.

Metformin adjustments based on renal function:

• eGFR ≥45: no restriction (max 2,550 mg/day for IR, 2,000 mg/day for ER)
• eGFR 30 to 44: do not initiate; if already on therapy, reduce to 500 to 1,000 mg/day
• eGFR <30: contraindicated

Rosuvastatin adjustments based on co-medications and genetics:

• No interacting drugs and wild-type SLCO1B1: up to 40 mg/day
• SLCO1B1 *5 heterozygous: consider 5 to 10 mg/day
• SLCO1B1 *5 homozygous: consider alternative statin or 5 mg/day max
• Severe renal impairment (CrCl <30): 10 mg/day max
• Cyclosporine co-use: 5 mg/day max

Metformin does not appear in the rosuvastatin label's drug interaction section. Rosuvastatin does not appear in the metformin label's drug interaction section.

Timing and Administration

Metformin immediate-release is typically taken twice daily with meals to reduce GI side effects. Metformin extended-release is taken once daily with the evening meal.

Rosuvastatin can be taken at any time of day, with or without food. Unlike some statins (simvastatin, lovastatin), rosuvastatin does not require evening dosing because its half-life (19 hours) provides continuous HMG-CoA reductase inhibition throughout the 24-hour cycle.

No specific spacing between the two drugs is needed. Patients who prefer simplicity can take rosuvastatin with their evening metformin dose.

When to Contact a Clinician

Patients taking both medications should seek medical evaluation if they experience:

• Unexplained muscle pain, tenderness, or weakness (could indicate statin myopathy; CK level needed)
• Dark or cola-colored urine (possible rhabdomyolysis; emergency evaluation)
• Nausea, vomiting, or abdominal pain with rapid breathing (possible metformin-associated lactic acidosis, especially if dehydrated or acutely ill)
• Yellowing of the skin or eyes (hepatic injury; obtain LFTs)

These events are rare. The combination of metformin and rosuvastatin has been used in clinical practice for over 15 years with a well-characterized safety profile.

Specific Populations

Older adults (≥65 years). Age-related declines in renal function may require metformin dose reduction. Rosuvastatin exposure increases modestly with age but does not require automatic dose adjustment. The 2018 AHA/ACC guideline recommends a clinician-patient risk discussion for statin initiation in adults over 75 [9].

Patients with NAFLD/MASH. Both drugs may confer hepatic benefit. Metformin reduces hepatic glucose output and has shown modest improvements in aminotransferases in NAFLD trials. Rosuvastatin improved steatosis scores in a subanalysis of the METEOR trial (N=702 with hepatic steatosis on ultrasound) [10]. Co-administration is generally continued in stable NAFLD.

Pregnancy and lactation. Both drugs are contraindicated in pregnancy. Metformin crosses the placenta. Rosuvastatin is classified as contraindicated (previously Category X). Women of reproductive age should use effective contraception.

Clinical Bottom Line

Metformin and rosuvastatin target complementary pathways in cardiometabolic disease and do not produce a clinically meaningful pharmacokinetic or pharmacodynamic interaction at standard doses. Routine co-prescription is supported by the ADA, AHA/ACC, and the FDA-approved labeling of both drugs. Monitor eGFR at least annually, obtain a lipid panel 4 to 12 weeks after statin initiation, and check CK only if the patient reports muscle symptoms.